Icon

COZAAR (nda020386)- (25MG,50MG,100MG)

LOSARTAN POTASSIUM ORGANON
25MG,50MG,100MG
Yes No
2014-Sep-04 Expired
None None
None No
COZAAR is an angiotensin II receptor blocker (ARB) indicated for: • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients. • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.
19 0 14
Total Other Developers 15
Drugs with Suitability No
25MG ** ** - - 12
50MG ** ** Up - 13
100MG ** ** Up - 12
NDA Sales Available Total Generic Sales Available
Yes 12
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country
****** ***** ****-**** ******** ***. *********** **** ****** ****, ********, **** (**) *****, ****** ****** (***) ***
****** ***** *** ***** ******* *********** **** **. **-*, ***** *-*, ***** ********** ****, *****, ********, *** ******, ***** (***) ***
****** ***** *** ***** ******* *********** ****-*, **** **. *-* *** *-*-*, ******* ******** **** ***** **, ****. ****, ******* ****, ****. ****, *********, ****** ******* ******, ***** (***) ***
****** ***** ****** *** *** ***** ************ ******* *********** ******* ****** *****, *.*. *****, ******-********, *****, ******** ******* ******, ***** (***) ***
****** ***** ****** *** *** ***** ************ ******* *********** ****** **. ***, *** & ***, ******* ***** ******** ******* ** * *, *******-*******, ***-******, ****. - *********, *********, ******* ******, ***** (***) ***
****** ********* ****** ******** ****** *** *********** **** ***** *** *****, ******, *** ****** (**) *****, ****** ****** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, **. **.*** & ***, **********, ********** ******, *******-********** ********, *******, ********* ******, ***** (***) ***
****** ********* ****** *** ********** ******* *********** ****-**, **** **.**, *****, *.*.***, ******** *******, ********* ******, ******** ********, ********, ****** ******* ******, ***** (***) ***
****** ******* ****** ******* ******* ******* ******* *********** **** **. ***, ***, ***, *** & ***, ***** ************** *******, *******, ************, ***** **** ******, ***** (***) ***
****** ******* ****** *** ******* *************** ******* *********** *********** ********, ******* *******, *.*. *******, **** *****, ****** *****,, **********, ******* ******, ***** (***) ***
****** ******* ****** *** ******* *************** ******* *********** *********** ******** **, ***** ****, *****, ****** ********, ********, ******* ******, ***** (***) ***
****** ******** *** ******** ****** ************** **., ***. *********** ******* ****, ******, ******** ******, ***** (***) ***
****** ***** **** ***** **** ******* *********** **** **. *-*** ** *-*** & **, ***** *** & ***** **, ***** ********** ******, *****, *** ******, ***** (***) ***
****** ******** ******* ******** ******* *************** ***. *********** *** ***** *****, *********, ******** (**) *****, ****** ****** (***) ***
****** ******** ****** *** ******** *************** ******* *********** ******* *****, **** ****** **********,****** *****, ******** *****, ******** ******* ******, ***** (***) ***
****** ******* ******* ************ ******* *********** *-**, ** & *-**, ********** ****, ****** ****, *********, ***** ******* ******, ***** (***) ***
****** ****** **** *** * ****** **** ******* *********** **** *, **. **.: ***, ***, *** & ***, ***** *********** ***, ********* *******, ************, ********* ******, ***** (***) ***
****** ****** **** *** * ****** *************** *** *********** *** * ********** **, ******* *****, *** **** (**) *****, ****** ****** (***) ***
****** *** *** ************ ******* ******* *********** *********** ********, **** -** **. **'* (***** **) : ***, *** , ***, ***, ***, ***, ***, ***- *** *** *** ******** (*******), ********* (******),, ********** (********), ********* ******, ***** (***) ***
****** ********* ****** ********* ****** ******* *********** ****-***, ** **. ***/*, ***/*, ***/*, ***/* & ***/*, **** ** **** ***, *****, ***** ********** ****, *********, ********* ******, ************, ********* ******, ***** (***) ***
****** ******** ******** *************** ***. *********** **** & **** ******** *******, *********, ******** (**) *****, ****** ****** (***) ***

Download GenUS Drug Report


Download GenUS Detailed Report


To get detailed report Contact Us

GenUs Advanced Search




Expired
to
Expired
to


Brand Name Generic Name Strength Dosage Route of Administration Innovator ParaIV

Please contact contact@researchdelta.com to get more details.